This molecular convergence underpins their “histology‐agnostic” targetability, exemplified by TRK inhibitors (larotrectinib/entrectinib) inducing responses in TPM3‐NTRK1+ colorectal carcinomas, gliomas, and sarcomas. This evidence concerns the gene TPM3 and sarcoma.